{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:40:37Z","timestamp":1776703237820,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To compare effectiveness of different treatments for atrial fibrillation (AF) patients who were scheduled for cardioversion (CV) or ablation (CA) presenting with left atrium appendage (LAA) thrombus despite chronic oral anticoagulation therapy (OAC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort study. We analyzed 2014\u20132019 medical records of patients scheduled for CV or CA of AF who were diagnosed with LAA thrombus despite optimal OAC and had a follow-up transesophageal echocardiogram (TOE). Changes in treatment were divided into the following groups: switch to a drug with different mechanism of action, switch to a drug with similar mechanism of action, initiation of combination therapy, or deliberate no change in treatment. Patients with contraindications to non-vitamin K antagonists were excluded from the analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed data of 129 patients comprising 181 cycles of treatment. The overall effectiveness of LAA thrombus dissolution was 51.9% regardless of the number of cycles and 42.6% for the first cycle of treatment. Any change of treatment was more effective than deliberate no change\u2014OR 2.97 [95% CI: 1.07\u20138.25], <jats:italic>P<\/jats:italic>\u2009=\u20090.031, but no particular strategy seemed to be more effective than the other. Left atrium area (OR 0.908 [95% CI: 0.842\u20130.979]) and number of treatment cycles (OR 0.457 [95% CI: 0.239\u20130.872]) were both adversely related to thrombus resolution. There was one ischemic and three bleeding adverse events during the treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LAA thrombus resolution in patients already on OAC may require a change of previous OAC treatment but the overall effectiveness of dissolution seems to be about 50%.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-021-07278-9","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T14:34:04Z","timestamp":1635172444000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Comparative Effectiveness and Safety of Different Anticoagulation Strategies for Treatment of Left Atrial Appendage Thrombus in the Setting of Chronic Anticoagulation for Atrial Fibrillation or Flutter"],"prefix":"10.1007","volume":"37","author":[{"given":"Karol","family":"Ko\u0142akowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142 M.","family":"Farkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Pytkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Gardziejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohdan","family":"Firek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Jaworski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Klisiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Maci\u0105g","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"issue":"8","key":"7278_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983\u20138.","journal-title":"Stroke"},{"issue":"5","key":"7278_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"key":"7278_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijcard.2018.03.068","volume":"266","author":"S Barra","year":"2018","unstructured":"Barra S, Baran J, Narayanan K, Boveda S, Fynn S, Heck P, et al. Association of catheter ablation for atrial fibrillation with mortality and stroke: a systematic review and meta-analysis. Int J Cardiol. 2018;266:136\u201342.","journal-title":"Int J Cardiol"},{"issue":"14","key":"7278_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305\u201316.","journal-title":"N Engl J Med"},{"key":"7278_CR5","doi-asserted-by":"publisher","first-page":"8181657","DOI":"10.1155\/2019\/8181657","volume":"2019","author":"M Ruzieh","year":"2019","unstructured":"Ruzieh M, Foy AJ, Aboujamous NM, Moroi MK, Naccarelli GV, Ghahramani M, et al. Meta-analysis of atrial fibrillation ablation in patients with systolic heart failure. Cardiovasc Ther. 2019;2019:8181657.","journal-title":"Cardiovasc Ther"},{"key":"7278_CR6","doi-asserted-by":"crossref","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;2021.","DOI":"10.1093\/europace\/euab157"},{"issue":"1","key":"7278_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/europace\/eux275","volume":"20","author":"H Calkins","year":"2018","unstructured":"Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2018;20(1):157\u2013208.","journal-title":"Europace"},{"issue":"1","key":"7278_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/europace\/euz257","volume":"22","author":"MM Farkowski","year":"2020","unstructured":"Farkowski MM, Jubele K, Mar\u00edn F, Gandjbakhch E, Ptaszynski P, Merino JL, et al. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. Europace. 2020;22(1):162\u20139.","journal-title":"Europace"},{"issue":"3","key":"7278_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.joa.2016.01.009","volume":"32","author":"Y Miwa","year":"2016","unstructured":"Miwa Y, Minamishima T, Sato T, Sakata K, Yoshino H, Soejima K. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J Arrhythm. 2016;32(3):233\u20135.","journal-title":"J Arrhythm"},{"issue":"1","key":"7278_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10840-019-00561-8","volume":"57","author":"F Squara","year":"2020","unstructured":"Squara F, Bres M, Scarlatti D, Moceri P, Ferrari E. Clinical outcomes after AF cardioversion in patients presenting left atrial sludge in trans-esophageal echocardiography. J Interv Card Electrophysiol. 2020;57(1):149\u201356.","journal-title":"J Interv Card Electrophysiol"},{"issue":"12","key":"7278_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jcmg.2014.08.009","volume":"7","author":"R Beigel","year":"2014","unstructured":"Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7(12):1251\u201365.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"7278_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s11239-018-1693-3","volume":"46","author":"E Ghaffarpasand","year":"2018","unstructured":"Ghaffarpasand E, Tehrani MD, Marszalek J, Chi G. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. J Thromb Thrombolysis. 2018;46(3):332\u20138.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"7278_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccep.2019.11.004","volume":"12","author":"G Murtaza","year":"2020","unstructured":"Murtaza G, Yarlagadda B, Akella K, Della Rocca DG, Gopinathannair R, Natale A, et al. Role of the left atrial appendage in systemic homeostasis, arrhythmogenesis, and beyond. Card Electrophysiol Clin. 2020;12(1):21\u20138.","journal-title":"Card Electrophysiol Clin"},{"issue":"5","key":"7278_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1253\/circj.CJ-16-1089","volume":"81","author":"M Kawabata","year":"2017","unstructured":"Kawabata M, Goya M, Sasaki T, Maeda S, Shirai Y, Nishimura T, et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy - warfarin vs direct oral anticoagulants. Circ J. 2017;81(5):645\u201351.","journal-title":"Circ J"},{"issue":"5","key":"7278_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.amjcard.2014.12.016","volume":"115","author":"MM Zylla","year":"2015","unstructured":"Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T, et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Am J Cardiol. 2015;115(5):635\u201340.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7278_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1160\/th15-07-0532","volume":"115","author":"MN Di Minno","year":"2016","unstructured":"Di Minno MN, Ambrosino P, Dello Russo A, Casella M, Tremoli E, Tondo C. Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature. Thromb Haemost. 2016;115(3):663\u201377.","journal-title":"Thromb Haemost"},{"issue":"3","key":"7278_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacep.2016.01.004","volume":"2","author":"D Frenkel","year":"2016","unstructured":"Frenkel D, D\u2019Amato SA, Al-Kazaz M, Markowitz SM, Liu CF, Thomas G, et al. Prevalence of left atrial thrombus detection by transesophageal echocardiography: a comparison of continuous non-vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2(3):295\u2013303.","journal-title":"JACC Clin Electrophysiol"},{"issue":"7","key":"7278_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.amjcard.2016.12.008","volume":"119","author":"J Wyrembak","year":"2017","unstructured":"Wyrembak J, Campbell KB, Steinberg BA, Bahnson TD, Daubert JP, Velazquez EJ, et al. Incidence and predictors of left atrial appendage thrombus in patients treated with nonvitamin K oral anticoagulants versus warfarin before catheter ablation for atrial fibrillation. Am J Cardiol. 2017;119(7):1017\u201322.","journal-title":"Am J Cardiol"},{"key":"7278_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ahj.2016.05.007","volume":"178","author":"GY Lip","year":"2016","unstructured":"Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126\u201334.","journal-title":"Am Heart J"},{"issue":"1","key":"7278_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1477-9560-11-26","volume":"11","author":"T Kawakami","year":"2013","unstructured":"Kawakami T, Kobayakawa H, Ohno H, Tanaka N, Ishihara H. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013;11(1):26.","journal-title":"Thromb J"},{"issue":"1","key":"7278_CR21","first-page":"1182","volume":"8","author":"B Vaquerizo","year":"2015","unstructured":"Vaquerizo B, Sami M. Left atrial appendage thrombus resolution with reduced dose apixaban. J Atr Fibrillation. 2015;8(1):1182.","journal-title":"J Atr Fibrillation"},{"issue":"4","key":"7278_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11239-012-0747-1","volume":"34","author":"A Vidal","year":"2012","unstructured":"Vidal A, Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34(4):545\u20137.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"7278_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11239-016-1421-9","volume":"43","author":"F Marsico","year":"2017","unstructured":"Marsico F, Cecere M, Parente A, Paolillo S, de Martino F, Dellegrottaglie S, et al. Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal. J Thromb Thrombolysis. 2017;43(2):139\u201348.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"7278_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.joa.2014.12.010","volume":"31","author":"H Mitamura","year":"2015","unstructured":"Mitamura H, Nagai T, Watanabe A, Takatsuki S, Okumura K. Left atrial thrombus formation and resolution during dabigatran therapy: a Japanese Heart Rhythm Society report. J Arrhythm. 2015;31(4):226\u201331.","journal-title":"J Arrhythm"},{"issue":"2","key":"7278_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5114\/aoms.2019.86616","volume":"16","author":"R Piotrowski","year":"2020","unstructured":"Piotrowski R, Zaborska B, Pilichowska-Paszkiet E, Sikora-Fr\u0105c M, Baran J, Ku\u0142akowski P. RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study. Arch Med Sci. 2020;16(2):289\u201396.","journal-title":"Arch Med Sci"},{"issue":"15","key":"7278_CR26","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.2169\/internalmedicine.56.8508","volume":"56","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Shinoda Y, Ikeoka K, Minamisaka T, Fukuoka H, Inui H, et al. Dabigatran therapy resulting in the resolution of rivaroxaban-resistant left atrial appendage thrombi in patients with atrial fibrillation. Intern Med. 2017;56(15):1977\u201380.","journal-title":"Intern Med"},{"issue":"17","key":"7278_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/heartjnl-2018-314492","volume":"105","author":"A Kap\u0142on-Cie\u015blicka","year":"2019","unstructured":"Kap\u0142on-Cie\u015blicka A, Budnik M, Gawa\u0142ko M, Peller M, Gorczyca I, Michalska A, et al. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. Heart. 2019;105(17):1310\u20135.","journal-title":"Heart"},{"key":"7278_CR28","doi-asserted-by":"publisher","first-page":"1683142","DOI":"10.1155\/2020\/1683142","volume":"2020","author":"X Zhou","year":"2020","unstructured":"Zhou X, Wang Z, Dou S, Chen K, Liu E, Liu T, et al. Biomarkers for predicting left atrial or left atrial appendage thrombus in anticoagulated patients with nonvalvular atrial fibrillation. Cardiol Res Pract. 2020;2020:1683142.","journal-title":"Cardiol Res Pract"},{"issue":"1","key":"7278_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.amjcard.2018.09.027","volume":"123","author":"AD Niku","year":"2019","unstructured":"Niku AD, Shiota T, Siegel RJ, Rader F. Prevalence and resolution of left atrial thrombus in patients with nonvalvular atrial fibrillation and flutter with oral anticoagulation. Am J Cardiol. 2019;123(1):63\u20138.","journal-title":"Am J Cardiol"},{"issue":"11","key":"7278_CR30","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1177\/1060028013504741","volume":"47","author":"T Hellwig","year":"2013","unstructured":"Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11):1478\u201387.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"7278_CR31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1160\/TH09-09-0659","volume":"103","author":"M Ufer","year":"2010","unstructured":"Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103(3):572\u201385.","journal-title":"Thromb Haemost"},{"issue":"12","key":"7278_CR32","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","volume":"49","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933\u201344.","journal-title":"Stroke"}],"updated-by":[{"DOI":"10.1007\/s10557-021-07286-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000}}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07278-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T09:13:53Z","timestamp":1673428433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7278"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07278-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"6 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10557-021-07286-9","URL":"https:\/\/doi.org\/10.1007\/s10557-021-07286-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Although this was a retrospective review of the medial records, we obtained the approval of the Local Bioethics Committee (IK-NPIA-0021\u2013105\/1819\/19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not required due to retrospective methodology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"MMF received lecturer fees from Pfizer and Boehringer Ingelheim, and RD received lecturer fees from Bayer and Boehringer Ingelheim. All the other authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}